Seeking Alpha
 

Harvard Apparatus Regenerative Technology, Inc. (HART)

- NASDAQ
  • Mon, Aug. 31, 1:07 PM
    • Thinly traded nano cap Harvard Apparatus Regenerative Technology (HART +33.7%) is up on almost an 8x surge in volume, albeit on turnover of less than 1M shares, in response to the announcement that Karolinska Institute's inquiry into alleged misconduct by visiting professor Paolo Macchiarini cleared him of all charges regarding his reporting of the status of three patients (two who died) who received a replacement trachea implanted by him. In May, an independent investigator accused Macchiarini of misrepresenting key aspects of papers describing the surgical procedures which misled readers into thinking the procedures were more successful than they actually were. Certain data in the papers could not be found in the medical records, for example.
    • Krolinska's probe did identify "certain circumstances" where the surgeon's work did not meet the university's high quality standards in every respect. He may have to submit amendments on several publications as a result. Also, allegations that he failed to get proper consents from patients before the operations are still being investigated.
    • Macchiarini's problems shut down the clinical development of regenerated replacement tracheas, which were supplied by HART.
    | Mon, Aug. 31, 1:07 PM | 12 Comments
  • Mon, Aug. 31, 12:47 PM
    | Mon, Aug. 31, 12:47 PM | 2 Comments
  • Thu, Aug. 13, 4:16 PM
    | Thu, Aug. 13, 4:16 PM | Comment!
  • Thu, Jun. 25, 1:07 PM
    • Harvard Apparatus Regenerative Technology (HART +3.1%) appoints Board member James McGorry as Chief Executive Officer effective July 6. Mr. McGorry, a member of the HART Board since February 2013, was most recently EVP and GM, Translational Oncology Solutions for Champions Oncology (OTCQB:CSBR).
    | Thu, Jun. 25, 1:07 PM | 1 Comment
  • Wed, May 27, 12:47 PM
    | Wed, May 27, 12:47 PM | 1 Comment
  • Thu, May 7, 8:45 AM
    | Thu, May 7, 8:45 AM | Comment!
  • Thu, Apr. 30, 12:17 PM
    • Greatbatch (GB +0.9%) intends to spin off Algostim, LLC, a subsidiary of its QiG Group, which was established in 2008 to develop a broad-based neurostimulation platform, of which the Algovita Spinal Cord Stimulation (SCS) system is the first application. Its intended indication is the treatment of chronic intractable pain of the trunk and/or limbs. A 3.5-year 200-patient clinical trial is set to commence shortly. The primary endpoint will be the percent reduction in pain at the six month post-implant follow-up visit.
    • The tax-free spin-off will create a new publicly traded company focused on commercializing the Algovita device. Greatbatch will provide additional details at a later date.
    • This is the same type of transaction that Harvard Bioscience (HBIO -7.5%) used to spin off Harvard Apparatus Regenerative Technology (HART -3.8%) in late 2013.
    | Thu, Apr. 30, 12:17 PM | Comment!
  • Thu, Apr. 16, 4:24 PM
    • Harvard Apparatus Regenerative Technology (NASDAQ:HART) President, CEO & Chairman David Green resigns in favor of a successor who has the skills and experience to lead the firm through the clinical development and commercialization of its regenerative medicine products. He will remain a member of the board of directors. The search for a replacement is underway.
    | Thu, Apr. 16, 4:24 PM | Comment!
  • Thu, Mar. 19, 9:41 AM
    • Harvard Apparatus Regenerative Technology (HART +1.5%) Q4 results: Revenues: $45K (+104.5%); COGS: $23K (+109.1%); R&D Expense: $1.3M (+18.2%); SG&A: $1.6M (-0.2%); Net Loss: ($2.8M) (-7.7%); Loss Per Share: ($0.36) (-5.9%).
    • FY2014 results: Revenues: $93K (+322.7%); COGS: $48K (+336.4%); R&D Expense: $5.1M (+10.9%); SG&A: $6M (+39.5%); Net Loss: ($11.1M) (-26.1%); Loss Per Share: ($1.41) (-23.7%); Quick Assets: $5.3M (-62.1%); CF Ops: ($8M) (-3.9%).
    • No guidance given.
    | Thu, Mar. 19, 9:41 AM | Comment!
  • Thu, Mar. 19, 8:07 AM
    • Harvard Apparatus Regenerative Technology (NASDAQ:HART): Q4 EPS of -$0.36 misses by $0.09.
    • Revenue of $0.05M (+150.0% Y/Y) beats by $0.03M.
    • Press Release
    | Thu, Mar. 19, 8:07 AM | Comment!
  • Wed, Feb. 18, 3:31 PM
    • Harvard Apparatus Regenerative Technology (HART +2.7%) closes its public offering of 2,070,000 shares, including the full exercise of the underwriters over-allotment of 270,000, of common stock at $1.75 per share  and 695,857 shares of Series B Convertible Preferred Stock at $8.75 per share. Each Series B share is convertible into five shares of common.
    • Net proceeds of $8.6M will fund R&D activities, operating expenses, capex and general corporate purposes.
    | Wed, Feb. 18, 3:31 PM | Comment!
  • Tue, Feb. 17, 1:07 PM
    • Thinly-traded nano cap Harvard Apparatus Regenerative Technology (HART +26.7%) heads north again on a 7x surge in volume albeit on turnover of less than 520K. Shares have jumped almost 80% since the company announced its equity offering that will raise ~$9M.
    • Previously: HART prices public offering (Feb. 12)
    | Tue, Feb. 17, 1:07 PM | Comment!
  • Tue, Feb. 17, 12:44 PM
    | Tue, Feb. 17, 12:44 PM | Comment!
  • Thu, Feb. 12, 10:43 AM
    • Harvard Apparatus Regenerative Technology (HART +12.7%) prices its public offering of 1.8M shares of common stock at $1.75 per share and its offering of 695,857 shares of Series B Convertible Preferred Stock at $8.75 per share. Each Series B share is convertible into five common shares. Gross proceeds will be ~$9.2M.
    • Underwriters over-allotment is an additional 270K shares of common. Closing date is February 18.
    • Net proceeds will fund R&D activities, operating expenses and general corporate purposes.
    | Thu, Feb. 12, 10:43 AM | 3 Comments
  • Wed, Feb. 11, 4:28 PM
    • Harvard Apparatus Regenerative Technology (NASDAQ:HART) commences a public offering of common stock and Series B Convertible Preferred Stock, each convertible into five shares of common. Underwriters over-allotment will be an additional 15% of the number of common shares offered. Terms and prices have yet to be announced.
    • Proceeds will fund R&D activities, clinical trials, operating expenses and general corporate purposes.
    | Wed, Feb. 11, 4:28 PM | 1 Comment
  • Mon, Feb. 2, 12:49 PM
    | Mon, Feb. 2, 12:49 PM | Comment!
Visit Seeking Alpha's
HART vs. ETF Alternatives
Company Description
Sector: Healthcare
Industry: Biotechnology
Country: United States